Select Your Plan

Completing the assessment on the Healthy Path Meds platform does not create a doctor-patient relationship between the individual and Healthy Path Meds. Beluga Health—a network of US-licensed physicians dedicated to strict medical protocols for patient safety—applies specific criteria to determine eligibility for compounded GLP-1 medications. Your responses in the Healthy Path Meds assessment will help determine if you are eligible. Acting as a facilitator, Healthy Path Meds connects eligible individuals with Beluga Health and its clinicians. Only Beluga Health clinicians make the decision to prescribe compounded medications, establishing the doctor-patient relationship directly with you. Healthy Path Meds does not directly provide medical or pharmacy services and payment does not guarantee the writing or dispensing of a prescription.

We offer compounded forms of semaglutide and liraglutide sourced exclusively from licensed and highly regulated U.S. pharmacies. These medications are not FDA-evaluated for safety, quality, or efficacy. The FDA does not review or approve any compounded medications for safety or effectiveness. Licensed physicians prescribe these compounds as part of our weight loss programs. Physicians may prescribe compounded medications to meet specific patient needs or address shortages. Actual product packaging may appear differently than shown.

FDA-approved brand-name medications such as Wegovy®, Saxenda® and Ozempic® are exclusively available from Novo Nordisk®. Healthy Path Meds is not affiliated with, nor endorsed by, any of the mentioned products or companies. We do not offer these products.

The information on this website is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. If you have any health-related questions or concerns, please consult your doctor.

*Studies show that individuals using semaglutide lost up to 16.9% body weight over a period of 68 weeks: Wilding J, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183.